These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18180487)

  • 1. Drug licenses: a new model for pharmaceutical pricing.
    Goldman DP; Jena AB; Philipson T; Sun E
    Health Aff (Millwood); 2008; 27(1):122-9. PubMed ID: 18180487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Market-based licensing for HPV vaccines in developing countries.
    Outterson K; Kesselheim AS
    Health Aff (Millwood); 2008; 27(1):130-9. PubMed ID: 18180488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
    Danzon PM; Towse A
    Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value-Based Pricing and Patient Access for Specialty Drugs.
    Robinson JC; Howell S; Pearson SD
    JAMA; 2018 Jun; 319(21):2169-2170. PubMed ID: 29801023
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmaceutical pricing: a review of proposals to improve access and affordability of prescription drugs.
    Tironi P
    Ann Health Law; 2010; 19(2):311-65, preceding i. PubMed ID: 21443147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescription-drug prices.
    Frank RG
    N Engl J Med; 2004 Sep; 351(14):1375-7. PubMed ID: 15459294
    [No Abstract]   [Full Text] [Related]  

  • 7. Regulation of pharmaceutical prices: evidence from a reference price reform in Denmark.
    Kaiser U; Mendez SJ; Rønde T; Ullrich H
    J Health Econ; 2014 Jul; 36():174-87. PubMed ID: 24879578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of incentive-based formularies on prescription-drug utilization and spending.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Frank RG
    N Engl J Med; 2003 Dec; 349(23):2224-32. PubMed ID: 14657430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compulsory licensing to regulated licensing: effects on the conflict between innovation and access in the pharmaceutical industry.
    Gillat A
    Food Drug Law J; 2003; 58(4):711-40. PubMed ID: 15027457
    [No Abstract]   [Full Text] [Related]  

  • 10. Can price and regulatory controls replace free market competition in the drug industry?
    Buc NL; Levitt GM
    Healthspan; 1993 Nov; 10(10):30-2. PubMed ID: 10130839
    [No Abstract]   [Full Text] [Related]  

  • 11. Lower Prices and Greater Patient Access - Lessons from Germany's Drug-Purchasing Structure.
    Robinson JC
    N Engl J Med; 2020 Jun; 382(23):2177-2179. PubMed ID: 32492300
    [No Abstract]   [Full Text] [Related]  

  • 12. The impact of 1990 Medicaid drug rebates policy on access to prescriptions.
    Okunade AA
    J Health Soc Policy; 2001; 12(3):33-51. PubMed ID: 11146982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The GO License: only part of the solution.
    Batson A; Milstien JB
    Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Burden of Federalism: Challenges to State Attempts at Controlling Prescription Drug Costs.
    Gudiksen KL; King JS
    J Leg Med; 2019; 39(2):95-120. PubMed ID: 31503534
    [No Abstract]   [Full Text] [Related]  

  • 15. Perverse incentives in the Medicare prescription drug benefit.
    McAdams D; Schwarz M
    Inquiry; 2007; 44(2):157-66. PubMed ID: 17850042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws.
    Dusetzina SB; Huskamp HA; Winn AN; Basch E; Keating NL
    JAMA Oncol; 2018 Jun; 4(6):e173598. PubMed ID: 29121177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients.
    Tseng CW; Brook RH; Keeler E; Mangione CM
    JAMA; 2003 Jul; 290(2):222-7. PubMed ID: 12851277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eliminating innovation: how price controls limit access.
    Ingram J
    J Leg Med; 2011 Jan; 32(1):115-28. PubMed ID: 21391059
    [No Abstract]   [Full Text] [Related]  

  • 19. Learning from practice: compulsory licensing cases and access to medicines.
    Stirner B
    Pharm Pat Anal; 2012 Nov; 1(5):555-75. PubMed ID: 24236925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. US lawmakers seek cuts in prescription drug prices.
    Jaffe S
    Lancet; 2019 Mar; 393(10175):975-976. PubMed ID: 30860040
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.